ArticleGynecologic oncology reports2025
Disparities in the uptake of HPV-related cancer prevention strategies among women by HIV status in Puerto Rico.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anal cancer risk factors and HPV infection knowledge and awareness among Hispanic persons living with HIV in Puerto Rico.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Women living with HIV (WLWH) are at increased risk of persistent HPV infection and HPV-related cancers than persons without HIV. We aimed to describe the utilization of primary and secondary prevention strategies for HPV-related cancers among women by HIV status in Puerto Rico (PR). Methods: We performed a secondary data analysis of women aged 21+ years (n = 469) evaluated at the Anal Neoplasia Clinic (ANC) of the University of Puerto Rico Comprehensive Cancer Center between 2014 and 2023. The outcomes were history of HPV vaccination, anal Pap screening, and cervical Pap screening in the past 3 years. Descriptive statistics were employed to characterize the study population and comparisons were made by HIV status. Results: Women's mean age in our study was 50.2 ± 12.1 years; 75.7 % were living with HIV. Among women who were age-eligible for HPV vaccination, 21.7 % reported receiving the HPV vaccine; WLWH were less likely vaccinated than women without HIV (14.7 % vs. 38.7 %, p < 0.01). Prevalence of cervical and anal Pap screening were significantly higher among WLWH (98.6 % and 89.9 %, respectively) than in women without HIV (94.4 % and 47.7 %, respectively). Several risk factors for HPV-related disease were more common among WLWH, such as age at first sexual encounter (≤ 16 years) (54.7 %), more than six lifetime sexual partners (43.1 %), and being a current smoker (23.6 %). Conclusions: Although we observed high uptake of cervical and anal Pap screening in this clinic-based sample, HPV vaccination was deficient. Future studies should involve developing tailored cancer prevention strategies for WLWH to increase HPV vaccination uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.